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Abstract
Objectives The objective of this study was to update an
in-depth analysis of the time trend for prostate cancer
(PCA) mortality in the population of Tyrol by 5 years,
namely to 2008. In Tyrol, prostate-speciﬁc antigen (PSA)
tests were introduced in 1988/89; more than three-quarters
of all men in the age group 45–74 had at least one PSA test
in the past decade.
Methods We applied the same model as in a previous
publication, i.e., an age-period-cohort model using Poisson
regression, to the mortality data covering more than three
decades from 1970 to 2008.
Results For Tyrol from 2004 to 2008 in the age group
60? period terms show a signiﬁcant reduction in prostate
cancer mortality with a risk ratio of 0.70 (95% conﬁdence
interval 0.57, 0.87) for Tyrol, and for Austria excluding
Tyrol a moderate reduction with a risk ratio of 0.92 (95%
conﬁdence interval 0.87, 0.97), each compared to the
mortality rate in the period 1989–1993.
Conclusions This update strengthens our previously
published results, namely that PSA testing offered to a
population at no charge can reduce prostate cancer mor-
tality. The extent of mortality reduction is in line with that
reported in the other recent publications. However, our data
do not permit us to fully assess the harms associated with
PCA screening, and no recommendation for PSA screening
can be made without a careful evaluation of overdiagnosis
and overtreatment.
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Introduction
Prostate cancer (PCA) is the second-leading cause of male
cancer death in most industrialized countries (Boyle et al.
2008). One out of six men in the United States and in most
industrialized countries will be affected by PCA during his
lifetime (SEER 2011). These facts explain why there is an
exceptional interest in scientiﬁcally proven evidence on
whether organized prostate-speciﬁc antigen (PSA) screen-
ing reduces PCA mortality and what harms are associated
with such screening. Until now, screening healthy men for
PCA has shown to be feasible and acceptable in the large
studies (De Koning et al. 2002). The results of two large
randomized studies with more than 75,000 cases and con-
trols in each study were recently published (Schro ¨der et al.
2009; Andriole et al. 2009), one showing a 20% reduction
in the PCA death rate with a p value of 0.04, and the other
showing no reduction.
Tyrol is one of the few countries where PSA testing was
introduced already as early as 1988/89, and since 1993 it
has been offered to all men aged 45–74 (Bartsch et al.
2001). In 2006, we published an analysis of PCA mortality
in Tyrol until the year of death 2003 and concluded that
PSA testing offered free of charge to a population can
reduce PCA mortality (Oberaigner et al. 2006). Critical
questions were raised about the short observation period
and too small numbers and therefore unstable results.
Recently, the mortality data for Austria to year of death
2008 were released, which enables us to update our anal-
ysis by adding 5 years to the observation period, namely
2004–2008.
Therefore, in order to determine whether PSA testing
might be able to reduce PCA mortality in Tyrol, our goal
was to update our analysis of PCA mortality in Tyrol by a
5-year period, namely by years of death 2004–2008.
Methods
Mortality data were analyzed for Tyrol, and for Austria
excluding Tyrol. In Austria, mortality data are collected by
Statistics Austria (Hansluwka 1989); details are described
elsewhere (Oberaigner et al. 2006). We analyzed all cases
coded for cause of death PCA as described above.
Population data are also collected by Statistics Austria.
Census data are available for the years 1971, 1981, 1991
and 2001; for intercensus, years population ﬁgures are
extrapolated based on births, deaths and migration
information.
The male population of Tyrol in the last year of obser-
vation, namely 2008, was 343,340, and of Austria
excluding Tyrol 3,715,295.
Analysis of mortality time trends was based on age-
period-cohort (APC) modeling (Clayton and Schifﬂers
1987a, b). APC models allow separate effects to be esti-
mated for age (A), period or year of death (P) and cohort
(C) by means of Poisson regression. The method is iden-
tical to that used in our previous publication and was
described there (Oberaigner et al. 2006).
We ﬁtted separate models for PCA mortality for Tyrol,
and for Austria excluding Tyrol. For Tyrol, the APC model
reaches 24 degrees of freedom (DF) and deviance 30.4,
which seems to be reasonably good. For Austria excluding
Tyrol, the APC model reaches 24 DF and deviance 103.0.
For every step in model extension, the likelihood ratio test
shows that the parameter effect is different from a zero
effect.Thus,itisjustiﬁedtoaddeachparameterstepbystep.
For statistical analysis, the number of PCA deaths was
aggregated in 5-year age groups, 5-year period groups and
consequently 5-year cohort groups. There are a very few
PCA deaths for age below 60 in Tyrol (3.3% of all PCA
deaths). We thus decided to build the model for age groups
beginning with age 60–64 and continue in 5-year age
groups. Our hypothesis was that the mortality rate
decreases following PSA testing, so the reference category
for period was 1989–1993.
In order to rule out the possibility that the choice of the
age of PCA deaths analyzed by us, namely 60?, had a
predominant inﬂuence on the result, we performed a sen-
sitivity analysis by applying the same model to age groups
50?, 50–74 and 60–74.
The analysis was performed with Stata Version 9, using
poisson procedure for Poisson regression (Stata Statistical
Software 2005).
Results
Basic numbers of PCA deaths and age-standardized rates
are given in Table 1; Fig. 1. Effects of the APC model are
described in Table 2; reference category for age is the age
group 60–64, for the period group 1989–1993 and for
cohort the cohort group 1882–1886. Figure 2 shows the
period effects for Tyrol and for Austria excluding Tyrol.
Age effects are of similar size for Tyrol and for Austria
excluding Tyrol: as compared to age group 60–64, the
effects are about 2, 5, 8, 14 and 22 for age groups 65–69,
70–74, 75–79, 80–84 and ?85, respectively.
Period effects, each compared to years of death
1989–1993, are about 0.7–0.8 for the 1970s and 1980s in
Tyrol, and about 0.9 for each of the two decades for Austria
excluding Tyrol; details are shown in Table 2; Fig. 2.I n
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123the time period after optional PSA testing was introduced
for all men in Tyrol, for Tyrol we observe effects of 0.97
(95% conﬁdence interval (CI) 0.84, 1.12), 0.86 (95% CI
0.72, 1.04) and 0.70 (95% CI 0.57, 0.87) for time periods
1994–1998, 1999–2003 and 2004–2008, respectively. For
Austria excluding Tyrol, we observe effects of 1 (95% CI
0.96, 1.04), 1.03 (95% CI 0.98, 1.08) and 0.92 (95% CI
0.87, 0.97), again for time periods 1994–1998, 1999–2003
and 2004–2008, respectively. The conﬁdence intervals for
the risk ratios for Tyrol and for Austria excluding Tyrol for
2004–2008 overlap only at the border.
For Tyrol, the cohort effects are about 1.5 until 1916,
after which we see a decrease to about 0.8 for cohorts born
after 1930. For Austria excluding Tyrol, the cohort effects
are rather stable with estimators between 1.20 and 1.40 and
about 1 for cohorts born after 1927.
By extending and/or subsetting the age of PCA deaths in
the analysis for the time period 2004–2008, we observe
estimators of 0.70 (95% CI 0.51, 0.95), 0.47 (95% CI 0.30,
0.75) and 0.40 (95% CI 0.26, 0.61) for age groups 50?,
50–74 and 60–74, respectively, each compared to
1989–1993. Details of period estimators are shown in
Table 3.
Discussion
Our analysis is based on an observational study of PCA
mortality data conducted in the population of Tyrol, where
PSA testing has been offered to men free of charge since it
was introduced in the early 1990s. For Tyrol, we observed
a mortality reduction of 14% for 1999–2003 and 30% for
2004–2008, and for Austria excluding Tyrol a mortality
reduction of 8% for 2004–2008. The reduction for
2004–2008 is statistically signiﬁcant for both Tyrol and
Austria excluding Tyrol.
Are observations for Tyrol and for Austria excluding
Tyrol plausible?
Our main study design is a historical comparison within
Tyrol. The second comparison, although not formally
Table 1 Prostate cancer mortality in Tyrol and in Austria excluding
Tyrol
Year of death Tyrol Austria excluding Tyrol
Number ASR
a Number ASR
a
1970 56 17.1 677 13.5
1971 41 12.6 695 13.5
1972 39 11.0 700 13.8
1973 56 15.9 779 14.9
1974 51 13.8 777 15.1
1975 47 13.3 771 14.7
1976 52 14.7 809 15.4
1977 50 13.7 779 14.2
1978 57 15.2 865 16.3
1979 68 18.0 783 14.4
1980 90 22.9 845 15.3
1981 52 13.4 849 15.3
1982 69 17.1 874 16.0
1983 61 15.2 837 15.1
1984 68 17.1 835 15.0
1985 76 17.7 905 15.5
1986 70 16.7 925 15.8
1987 87 20.9 984 16.9
1988 71 15.7 941 16.2
1989 72 15.3 986 17.0
1990 96 20.3 1,014 16.8
1991 96 21.0 1,110 18.3
1992 91 18.3 1,048 17.1
1993 96 20.4 1,081 17.7
1994 95 19.5 993 16.1
1995 93 19.2 1,109 17.4
1996 91 17.8 1,079 16.9
1997 88 15.9 1,096 16.9
1998 60 11.3 1,079 16.1
1999 79 14.2 1,143 16.9
2000 79 13.7 1,150 16.5
2001 85 14.8 1,099 16.1
2002 79 14.0 1,059 15.2
2003 68 11.6 1,092 15.5
2004 59 10.2 1,080 14.8
2005 62 9.7 1,035 13.7
2006 68 10.5 1,015 12.8
2007 74 11.2 992 12.1
2008 63 9.0 1,121 12.9
a Age-standardized rate per 100,000 using SEGI weights
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Fig. 1 Prostate cancer mortality: age-standardized rate in Tyrol and
in Austria excluding Tyrol for years of death 1970–2008 (vertical line
is end of previous publication)
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123included in the model, is between Tyrol and Austria
excluding Tyrol. In the absence of PSA testing, we have
good reasons to assume parallel time trends in PCA mor-
tality in both regions, because health services in general as
well as the diagnosis and therapy for cancer patients are
uniform throughout Austria. Therefore, it is likely that the
reduction in PCA mortality in Tyrol is mostly due to PSA
testing, which was the main difference in PCA manage-
ment between Tyrol and Austria excluding Tyrol up to
2000. In Tyrol, PSA cutoff levels equalled to 2.5, 3.5, 4.5
and 6.5 in age groups 40–49, 50–59, 60–69 and 70–79,
respectively, up to October 1996 and were cut in half to
1.25, 1.75, 2.25 and 3.25 in the same age groups mentioned
above (Bartsch 2008). Nevertheless, some smaller part of
the reduction could be a consequence of other unknown
factors. Whereas in Tyrol, PSA testing was introduced
already in the early 1990s, in Austria excluding Tyrol PSA
testing began some 7–10 years later. A look at PCA inci-
dence (Statistics Austria 2008) supports this interpretation
(see Fig. 3), because to our knowledge the introduction of
PSA testing is the only possible explanation for the sharp
increase in PCA incidence in Austria excluding Tyrol
between 1995 and 2000. Hence, the 8% PCA mortality
reduction in Austria excluding Tyrol could also be due to
PSA testing.
Compared to the literature, what this study adds
to known facts?
It is well known that observational studies are prone to a
number of possible biases (e.g. confounding), and we
expect much stronger evidence from randomized studies.
To date, we know of results from four randomized studies
on PSA screening and mortality, see (Boyle and Brawley
2009) for a discussion of the randomized studies. However,
due to contamination and attendance, the true value of
screening could have been underestimated (van Leeuwen
et al. 2010). Therefore, efforts have been taken to control
for contamination and attendance in the ERSPC studies,
and after correcting for these biases our result is in line
with other results, see for example (Robool et al. 2009, van
Leeuwen et al. 2010, Kerkhoff et al. 2010, Hugosson et al.
2010), bearing in mind that our approach is rather con-
servative because we have no age limit on PCA mortality
cases.
The number needed to treat was reduced from 1,410 in
the ERSPC study (Schro ¨der et al. 2009) to 293 in the
Go ¨teburg study (Hugosson et al. 2010). Therefore, we feel
it is time to revise the conclusion drawn by Boyle and
Brawley, which was based on the original ERSPC results.
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Fig. 2 Prostate cancer mortality in Tyrol and in Austria excluding
Tyrol for years of death 1970–2008, age 60?: estimated period
effects
Table 2 Results of the age-period-cohort model, drift in cohort
Tyrol Austria excluding Tyrol
Estimator 95% CI Estimator 95% CI
Age
60–64 1.00 Reference 1.00 Reference
65–69 2.05 1.65, 2.57 2.24 2.12, 2.38
70–74 4.63 3.73, 5.74 4.38 4.14, 4.64
75–79 7.86 6.23, 9.92 8.43 7.93, 8.97
80–84 13.29 10.23, 17.27 14.44 13.46, 15.48
?85 21.40 16.00, 28.62 23.65 21.88, 25.57
Period
1970–1973 0.66 0.50, 0.86 0.86 0.80, 0.93
1974–1978 0.62 0.49, 0.79 0.88 0.83, 0.94
1979–1983 0.78 0.65, 0.94 0.86 0.82, 0.91
1984–1988 0.81 0.70, 0.95 0.91 0.87, 0.95
1989–1993 1.00 Reference 1.00 Reference
1994–1998 0.97 0.84, 1.12 1.00 0.96, 1.04
1999–2003 0.86 0.72, 1.04 1.03 0.98, 1.08
2004–2008 0.70 0.57, 0.87 0.92 0.87, 0.97
Cohort
1882–1886 1.00 Reference 1.00 Reference
1887–1891 1.49 0.93, 2.38 1.24 1.10, 1.40
1892–1896 1.59 1.05, 2.42 1.27 1.14, 1.41
1897–1901 1.74 1.18, 2.55 1.35 1.22, 1.49
1902–1906 1.55 1.08, 2.24 1.41 1.28, 1.55
1907–1911 1.40 0.98, 2.00 1.44 1.31, 1.58
1912–1916 1.42 0.99, 2.03 1.43 1.30, 1.58
1917–1921 1.21 0.84, 1.74 1.29 1.17, 1.42
1922–1926 0.97 0.66, 1.42 1.14 1.03, 1.27
1927–1931 0.79 0.53, 1.20 1.10 0.98, 1.23
1932–1936 0.79 0.50, 1.25 1.05 0.92, 1.18
1937–1941 0.80 0.48, 1.34 0.89 0.77, 1.03
1942–1946
a
a Because there is drift in cohort, there is no estimator for the last
cohort 1942–1946
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123The advantage of our study is that it permits us to
investigate the effect of PSA screening in a real-life situ-
ation. While randomised studies concentrate on the efﬁcacy
of screening, we analyze the effectiveness of a PSA testing
program conducted in a well-deﬁned population. But, of
course, we cannot overcome problems that are inherent to
nonrandomised studies.
In order to rule out the possibility that the model
choice had a predominant effect, we compared our results
with results obtained with a joinpoint regression model.
We applied the SEER package (Joinpoint 2010, Kim et al.
2000), see Fig. 4. The results ﬁt to the results obtained
with the APC model, with a reduction in Tyrol beginning
at about 1990 and in Austria excluding Tyrol at about
2000. The size of the mortality decrease given by the
joinpoint regression model is even greater, meaning our
estimates are rather conservative. In addition, we con-
ducted a sensitivity analysis of the inﬂuence of age by
extending and/or subsetting the analysis to age groups
50?, 50–74 and 60–74 (see Table 3) and obtained stable
estimates.
Limitations
The facts that PSA testing was already introduced in Tyrol
around 1990 and that about three-fourths of all men aged
45–74 have undergone at least one PSA test for screening
purposes seem to be good reasons for conducting this
analysis. However, we are faced with severe limitations.
First, and this is probably the most severe limitation, our
analysis is based on an observational design, which does
not allow for any control of confounders. We conducted a
comparison with a historical control group and attributed
the main effect to PSA testing. Of course, we cannot rule
out the possibility that other factors contributed to the
reduction in PCA mortality.
Second, the outcome measure we analyzed is PCA
mortality, and we have no validation of PCA as cause of
death. We know that mortality statistics in Austria has been
of high quality for decades (Hansluwka 1989). Linking
Table 3 Sensitivity analysis of the age-period-cohort model by subsetting age groups, period estimators
Age 50? Age 50–74 Age 60–74
Estimator 95% CI Estimator 95% CI Estimator 95% CI
Period
1970–1973 0.66 0.44, 0.99 0.62 0.34, 1.13 0.59 0.37, 0.96
1974–1978 0.63 0.45, 0.87 0.62 0.3, 1.03 0.59 0.37, 0.93
1979–1983 0.78 0.61, 0.99 0.73 0.49, 1.11 0.70 0.46, 1.04
1984–1988 0.82 0.70, 0.98 0.99 0.73, 1.36 0.96 0.69, 1.34
1989–1993 1.00 Reference 1.00 Reference 1.00 Reference
1994–1998 0.95 0.80, 1.12 0.86 0.64, 1.17 0.90 0.66, 1.23
1999–2003 0.86 0.68, 1.09 0.62 0.42, 0.92 0.55 0.37, 0.80
2004–2008 0.70 0.51, 0.95 0.47 0.30, 0.75 0.40 0.26, 0.61
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Fig. 3 Prostate cancer incidence: age-standardized rate in Tyrol and
in Austria excluding Tyrol for years of diagnosis 1983–2007
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Fig. 4 Prostate cancer mortality in Tyrol and in Austria excluding
Tyrol for years of death 1970–2008: result of joinpoint regression for
age-speciﬁc rate age 60?. Annual percentage change for Tyrol 2.8*
(1970–1992), -5.3* (1992–2008) and for Austria excluding Tyrol
3.6* (1970–1978), 1.4* (1978–1991), -0.3 (1991–1999), -3.8*
(1999–2006), 2.4 (2006–2008), *denoting statistical signiﬁcance
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123mortality data with the Cancer Registry data gives an
estimate of false-positive PCA deaths: about 95% of those
PCA deaths showed a PCA diagnosis in the Cancer Reg-
istry database. This proportion does not change over time
(data not shown).
Third, we have no detailed knowledge of the volume of
PSA testing. For Tyrol, we collected data from all PSA labs
and estimated the PSA testing rate. After 9 years of intense
PSA testing, we estimate that 75.1% of all men aged 45–74
in Tyrol have had at least one PSA screening test (Obe-
raigner et al. 2006).
Fourth, we have only a very limited data on harms
caused by PSA testing. Pelzer analyzed 1,445 consecutive
patients undergoing radical prostatectomy at the Depart-
ment of Urology of Innsbruck Medical University and
concluded that the rate of overdiagnosis is small (between
8 and 17%), but also noticed underdiagnosis (Pelzer 2008).
After weighing all limitations and strengths, our per-
sonal estimate is that although these limitations exist and
cannot be formally ruled out, it is unlikely that all possible
biases could have caused a 50% reduction in PCA mor-
tality in men aged 50–74, albeit some part of this reduction
can be due to a combination of biases.
Our study concerns a well-deﬁned population of Tyrol,
where we have some knowledge of PSA testing rates and
information on therapy offered to the population. The APC
model ﬁts well for Tyrol, and when compared to Austria
excluding Tyrol the PSA testing rate seems to be the main
factor which is able to explain the difference in time trends
between Tyrol and Austria excluding Tyrol. Of course, our
analysis cannot overcome the problems of nonrandomized
studies, but it can provide further information on the
potential beneﬁts of PSA testing or screening.
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